{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T13:11:36Z","timestamp":1721826696283},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s40268-014-0050-z","type":"journal-article","created":{"date-parts":[[2014,6,10]],"date-time":"2014-06-10T19:34:50Z","timestamp":1402428890000},"page":"155-158","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Etanercept-Associated Transient Bone Marrow Aplasia: A Review of the Literature and Pathogenetic Mechanisms"],"prefix":"10.1007","volume":"14","author":[{"given":"Natasha","family":"Kozak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ami","family":"Schattner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,6,11]]},"reference":[{"key":"50_CR1","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1136\/ard.2004.024737","volume":"63","author":"KL Hyrich","year":"2004","unstructured":"Hyrich KL, Silman AJ, Watson KD, Symmons DPM. Anti-tumour necrosis factor \u03b1 therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis. 2004;63:1538\u201343.","journal-title":"Ann Rheum Dis"},{"key":"50_CR2","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","volume":"72","author":"G Burmester","year":"2013","unstructured":"Burmester G, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23,458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn\u2019s disease. Ann Rheum Dis. 2013;72:517\u201324.","journal-title":"Ann Rheum Dis"},{"key":"50_CR3","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1136\/ard.2006.056176","volume":"65","author":"S Rajakulendran","year":"2006","unstructured":"Rajakulendran S, Gadsby K, Allen D, et al. Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis. Ann Rheum Dis. 2006;65:1678\u20139.","journal-title":"Ann Rheum Dis"},{"key":"50_CR4","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","volume":"343","author":"JM Bathon","year":"2000","unstructured":"Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343:1586\u201393.","journal-title":"N Engl J Med"},{"key":"50_CR5","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/acr.20037","volume":"62","author":"R Hastings","year":"2010","unstructured":"Hastings R, Ding T, Butt S, et al. Neutropenia in patients receiving anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken). 2010;62:764\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"50_CR6","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1365-2036.2012.05189.x","volume":"36","author":"T Bessissow","year":"2012","unstructured":"Bessissow T, Renard M, Hoffman I, et al. Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy. Aliment Pharmacol Ther. 2012;36:312\u201323.","journal-title":"Aliment Pharmacol Ther"},{"key":"50_CR7","doi-asserted-by":"crossref","first-page":"E238","DOI":"10.7326\/0003-4819-139-3-200308050-00021-w4","volume":"139","author":"F Vidal","year":"2003","unstructured":"Vidal F, Fontova R, Richart C. Severe neutropenia and thrombocytopenia associated with infliximab. Ann Intern Med. 2003;139:E238\u20139.","journal-title":"Ann Intern Med"},{"key":"50_CR8","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/rheumatology\/ket233","volume":"52","author":"DE Furst","year":"2013","unstructured":"Furst DE, Kay J, Wasko MC, et al. The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Rheumatology (Oxford). 2013;52:1845\u201355.","journal-title":"Rheumatology (Oxford)"},{"key":"50_CR9","unstructured":"US FDA. Safety update on TNF-\u03b1 antagonists: infliximab and etanercept. http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/01\/briefing\/3779b2_01_cber_safety%20_revision2.pdf ."},{"key":"50_CR10","first-page":"247","volume":"23","author":"EG Favalli","year":"2005","unstructured":"Favalli EG, Varenna M, Sinigaglia L. Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy. Clin Exp Rheum. 2005;23:247\u201350.","journal-title":"Clin Exp Rheum"},{"key":"50_CR11","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/art.10885","volume":"48","author":"P Quartier","year":"2003","unstructured":"Quartier P, Taupinv P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003;48:1093\u2013101.","journal-title":"Arthritis Rheum"},{"key":"50_CR12","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/rheumatology\/keg341","volume":"42","author":"Y Menon","year":"2003","unstructured":"Menon Y, Cucurulli E, Espinoza LR. Pancytopenia in a patient with scleroderma treated with infliximab. Rheumatology. 2003;42:1273\u20134.","journal-title":"Rheumatology"},{"key":"50_CR13","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1034\/j.1600-0609.2003.00115.x","volume":"71","author":"J Kuruvilla","year":"2003","unstructured":"Kuruvilla J, Leitch HA, Vickars L, et al. Aplastic anemia following administration of a tumor necrosis factor-\u03b1 inhibitor. Eur J Haematol. 2003;71:396\u20138.","journal-title":"Eur J Haematol"},{"key":"50_CR14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/rheumatology\/key051","volume":"42","author":"A Marchesoni","year":"2003","unstructured":"Marchesoni A, Arreghini M, Panni B, Battafarano N, Uziel L. Life-threatening bone marrow toxicity in a rheumatoid arthritis patient switched from leflunomide to infliximab. Rheumatology. 2003;42:193\u20134.","journal-title":"Rheumatology"},{"key":"50_CR15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000080075","volume":"70","author":"J Seiderer","year":"2004","unstructured":"Seiderer J, Goke B, Ochsenkuhn T. Safety aspects of infliximab in inflammatory bowel disease patients. Digestion. 2004;70:3\u20139.","journal-title":"Digestion"},{"key":"50_CR16","unstructured":"Ben-Salem C, Jeddi C, Fathalla N, et al. Infliximab-induced bone marrow aplasia and vasculitis. In: ISoP 9th annual Meeting, Reims, France, 2009, Abstract 10."},{"issue":"Suppl 1","key":"50_CR17","first-page":"111","volume":"12","author":"SE Jacobsen","year":"1994","unstructured":"Jacobsen SE, Jacobsen FW, Fahlman C, Rusten LS. TNF-alpha, the great imitator: role of p55 and p75 TNF receptors in hematopoiesis. Stem Cells. 1994;12(Suppl 1):111\u201326.","journal-title":"Stem Cells"},{"key":"50_CR18","doi-asserted-by":"crossref","unstructured":"Schuettpelz LG, Link DC. Regulation of hematopoietic stem cell activity by inflammation. Front Immunol. 2013;4:204. doi: 10.3389\/fimmu.2013.00204 . eCollection 2013.","DOI":"10.3389\/fimmu.2013.00204"},{"key":"50_CR19","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1046\/j.1365-2141.2001.03212.x","volume":"115","author":"C Dufour","year":"2001","unstructured":"Dufour C, Corcione A, Svahn J, et al. Interferon gamma and tumour necrosis factor alpha are overexpressed in bone marrow T lymphocytes from paediatric patients with aplastic anaemia. Br J Haematol. 2001;115:1023\u201331.","journal-title":"Br J Haematol"},{"key":"50_CR20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1600-0609.2004.00259.x","volume":"73","author":"T Hara","year":"2004","unstructured":"Hara T, Ando K, Tsurumi H, Moriwaki H. Excessive production of tumor necrosis factor-alpha by bone marrow T lymphocytes is essential in causing bone marrow failure in patients with aplastic anemia. Eur J Haematol. 2004;73:10\u20136.","journal-title":"Eur J Haematol"},{"key":"50_CR21","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.3324\/haematol.2009.007815","volume":"94","author":"C Dufour","year":"2009","unstructured":"Dufour C, Ferretti E, Bagnasco F, et al. Changes in cytokine profile pre- and post-immunosuppression in acquired aplastic anemia. Haematologica. 2009;94:1743\u20137.","journal-title":"Haematologica"},{"key":"50_CR22","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/pbc.21886","volume":"52","author":"C Dufour","year":"2009","unstructured":"Dufour C, Giacchino R, Ghezzi P, et al. Etanercept as a salvage treatment for refractory aplastic anemia. Pediatr Blood Cancer. 2009;52:522\u20135.","journal-title":"Pediatr Blood Cancer"},{"key":"50_CR23","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.3109\/10428194.2011.568646","volume":"52","author":"W Fureder","year":"2011","unstructured":"Fureder W, Valent P. Treatment of refractory or relapsed acquired aplastic anemia: review of established and experimental approaches. Leuk Lymphoma. 2011;52:1435\u201345.","journal-title":"Leuk Lymphoma"},{"key":"50_CR24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4049\/jimmunol.180.1.49","volume":"180","author":"F Rezzoug","year":"2008","unstructured":"Rezzoug F, Huang Y, Tanner MK, et al. TNF-alpha is critical to facilitate hemopoietic stem cell engraftment and function. J Immunol. 2008;180:49\u201357.","journal-title":"J Immunol"},{"key":"50_CR25","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/MOH.0b013e3282fa7470","volume":"15","author":"NS Young","year":"2008","unstructured":"Young NS, Scheinberg P, Calado RT. Aplastic anemia. Curr Opin Hematol. 2008;15:162\u20138.","journal-title":"Curr Opin Hematol"},{"key":"50_CR26","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","volume":"86","author":"M Ramos-Casals","year":"2007","unstructured":"Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies. Medicine. 2007;86:242\u201351.","journal-title":"Medicine"},{"key":"50_CR27","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1592\/phco.30.4.339","volume":"30","author":"A Wiens","year":"2010","unstructured":"Wiens A, Venson R, Correr CJ, Otuki MF, Pontarolo R. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy. 2010;30:339\u201353.","journal-title":"Pharmacotherapy"},{"key":"50_CR28","doi-asserted-by":"crossref","unstructured":"Lethaby A, Lopez-Olivo MA, Maxwell L, et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Databases Syst Rev. 2013;(5):CD004525.","DOI":"10.1002\/14651858.CD004525.pub2"},{"key":"50_CR29","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1517\/14740338.2014.899579","volume":"13","author":"G Murdaca","year":"2014","unstructured":"Murdaca G, Spano F, Contratore M, et al. Efficacy and safety of etanercept in chronic immune-mediated disease. Expert Opin Drug Saf. 2014;13:649\u201361.","journal-title":"Expert Opin Drug Saf"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-014-0050-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-014-0050-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-014-0050-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,11]],"date-time":"2019-08-11T11:42:49Z","timestamp":1565523769000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-014-0050-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["50"],"URL":"https:\/\/doi.org\/10.1007\/s40268-014-0050-z","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}